3-MeO-PCE

3-Methoxyeticyclidine, also known as methoxieticyclidine, is a dissociative anesthetic that is qualitatively similar to PCE and PCP and has been sold online as a designer drug.
On October 18, 2012, the Advisory Council on the [Misuse of Drugs] in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Drugs controlled by [the UK Misuse of Drugs Act|Class B] of the Misuse of [Drugs Act 1971|Misuse of Drugs Act (1971)]", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of methoxetamine should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCE.
This report also described the receptor binding profile of methoxetamine and three additional dissociatives 3-MeO-PCP, 4-MeO-PCP, and 3-MeO-PCE, showing them to have significant affinity for the PCP site of the NMDA receptor and was later published in more detail.
3-MeO-PCE has K_i values of 61 nM for the NMDAR, 743 nM for the dopamine transporter, 2097 nM for the histamine [H2 receptor], 964 nM for the alpha-2A [adrenergic receptor], 115 nM for the serotonin transporter, 4519 nM for the σ₁ receptor, and 525 nM for the σ₂ receptor.

Legal status

3-MeO-PCE is banned in Sweden and Switzerland.
As per Chile's Ley [de drogas (Chile)|Ley de drogas], aka Ley 20000, all esters and ethers of PCE are illegal. As 3-MeO-PCE is an ether of PCE, it is thus illegal.